Gilead Sciences 2 articles

Gilead Sciences occupies a defined biopharma niche through antiviral therapeutics and oncology therapeutics, consistent with its role as a biopharmaceutical company focused on antiviral and oncology medicines. The biotechnology scope of Gilead Sciences spans CAR-T cell therapy through Kite, cell therapy manufacturing and antibody-drug conjugate oncology; these features distinguish Gilead Sciences within its disease and mechanism context. The entity represented here is Gilead Sciences, not a specific medicine; inflammation therapeutics provides an additional marker of its biotechnology scope.

Clinical Trials & Evidence

September 23, 2026, 11:12 PM · 5 mins read

Gilead ramps up cancer drug trials in Korea, shifting focus beyond antivirals

Gilead Sciences Korea now runs 60 percent of the company’s global cancer drug trials, marking a sharp turn from its antiviral roots as it celebrates 15 years in the country.

Clinical Trials & Evidence

September 23, 2026, 4:33 PM · 4 mins read

Gilead Korea pushes into CAR-T therapies and new drugs in major expansion

Marking 15 years in Korea, Gilead is moving into CAR-T therapies and plans to launch ten new drugs by 2027. The company is stepping beyond its viral disease roots and betting big on cancer and inflammation.